Zobrazeno 1 - 10
of 243
pro vyhledávání: '"David M. Pariser"'
Autor:
Steven R. Feldman, Joseph F. Merola, David M. Pariser, Jingchuan Zhang, Yang Zhao, Alan M. Mendelsohn, Alice B. Gottlieb
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 3, Pp 1670-1675 (2022)
Objective To evaluate whether early Psoriasis Area Severity Index (PASI) improvements can predict week 28 tildrakizumab responders and nonresponders. Methods Psoriasis patients pooled from two tildrakizumab phase 3 trials randomized to receive tildra
Externí odkaz:
https://doaj.org/article/7a3d19111209430ca2eac8a8f1badb80
Autor:
Jonathan S. Zager, Brian R. Gastman, Sancy Leachman, Rene C. Gonzalez, Martin D. Fleming, Laura K. Ferris, Jonhan Ho, Alexander R. Miller, Robert W. Cook, Kyle R. Covington, Kristen Meldi-Plasseraud, Brooke Middlebrook, Lewis H. Kaminester, Anthony Greisinger, Sarah I. Estrada, David M. Pariser, Lee D. Cranmer, Jane L. Messina, John T. Vetto, Jeffrey D. Wayne, Keith A. Delman, David H. Lawson, Pedram Gerami
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP’s pr
Externí odkaz:
https://doaj.org/article/51ad8d737b2d423ab145b5125b6bb24a
Autor:
Andrew Blauvelt, David M. Pariser, Stephen Tyring, Jerry Bagel, Andrew F. Alexis, Jennifer Soung, April W. Armstrong, Elisa Muscianisi, Farid Kianifard, Jennifer Steadman, Rajendra Prasad Sarkar, Sandra Garcet, James G. Krueger
Publikováno v:
Journal of Dermatological Science. 109:12-21
Autor:
Linda Stein Gold, Javier Alonso-Llamazares, Zoe D. Draelos, Melinda J. Gooderham, Steven E. Kempers, Leon H. Kircik, Mark G. Lebwohl, Kim A. Papp, David M. Pariser, Darryl P. Toth, Gil Yosipovitch, Robert C. Higham, Amy Feng, David R. Berk
Publikováno v:
American Journal of Clinical Dermatology. 24:305-313
Autor:
Zoe D Draelos, David N Adam, H Chih-ho Hong, Mark G Lebwohl, Charles W Lynde, Walter K Nahm, Kim A Papp, David M Pariser, Linda Stein Gold, Daniel Stewart, Robert C Higham, David R Berk, David Krupa, Patrick Burnett
Publikováno v:
British Journal of Dermatology. 188:810-812
This post hoc analysis evaluated efficacy and safety of roflumilast cream in patients with psoriasis involving the face/neck or intertriginous areas from a phase IIb trial. Of 331 patients enrolled in the phase IIb trial, 160 had psoriasis involving
Autor:
Matthew J. Zirwas, Zoe D. Draelos, Janet DuBois, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence J. Green, Scott T. Guenthner, Laura K. Ferris, Seth B. Forman, Steven E. Kempers, Edward Lain, Charles W. Lynde, David M. Pariser, Darryl P. Toth, Paul S. Yamauchi, Robert C. Higham, David Krupa, Patrick Burnett, David R. Berk
Publikováno v:
JAMA Dermatology.
ImportanceCurrent topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.ObjectiveTo assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/
Autor:
Jerry, Bagel, Tien Q, Nguyen, Hermenio, Lima, Neal, Jain, David M, Pariser, Sylvia, Hsu, Gil, Yosipovitch, Haixin, Zhang, Jingdong, Chao, Shikha, Bansal, Zhen, Chen, Daniel, Richman, Andrew, Korotzer, Marius, Ardeleanu
Publikováno v:
Dermatology and Therapy. 12:1417-1430
Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada.PROSE is an ongoing, longitudinal, prospective, observat
Autor:
Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball
Publikováno v:
Tha?i, D, Vender, R, de Rie, M A, Conrad, C, Pariser, D M, Strober, B, Vanvoorden, V, Wang, M, Madden, C, de Cuyper, D & Kimball, A B 2023, ' Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis : longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial ', British Journal of Dermatology, vol. 188, no. 1, pp. 22-31 . https://doi.org/10.1093/bjd/ljac021
British Journal of Dermatology, 188(1), 22-31. Wiley-Blackwell
British Journal of Dermatology, 188(1), 22-31. Wiley-Blackwell
Background BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings. Objectives To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9987cd699828d991ef25e576c63d8b1f
https://research.vumc.nl/en/publications/a9a82c67-83e7-4154-8697-655c76349821
https://research.vumc.nl/en/publications/a9a82c67-83e7-4154-8697-655c76349821
Autor:
Yao Wang, Lawrence Green, Howard Sofen, David M. Pariser, Lorne Albrecht, Kim A. Papp, Kristina Callis Duffin, Melinda Gooderham, Linda Stein Gold, Maria Paris, Neal Bhatia, M. Chen
Publikováno v:
Journal of the American Academy of Dermatology. 86:77-85
Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment.To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis.Phase 3, double-blind, placebo-controlled study in adults with mild-to-moderate psoriasis
Autor:
Tobin J. Dickerson, Courtney Boyce, Byung-In Lee, Tatiana Tomich, Christian Abaya, Alan Menter, Paul Montgomery, David M. Pariser, Yipeng Wang, Jerry Bagel, Eric Andrade
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:621-638
Objective: This study was designed to develop and prospectively validate a machine learning based algorithm that could predict patient response to the most common biologic drug classes used in the management of psoriasis patients. This type of tool w